HomeInvestors & MediaNews
- Milestone of 5 million dollars
- ABL301 Phase 1 clinical trial is underway in the U.S…. From Phase 2 studies Sanofi will conduct the trials
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has completed the manufacturing technology transfer for ABL301, a bispecific antibody candidate for the treatment of neurodegenerative diseases including Parkinson’s disease, to Sanofi, and will receive a milestone of $5 million.
ABL301 is a bispecific antibody pipeline that enhances potential therapeutic efficacy against Parkinson’s Disease by effectively carrying the anti-alpha-synuclein antibody into the brain utilizing Grabody-B platform technology of ABL Bio. Grabody-B platform targets the insulin-like growth factor 1 receptor (IGF1R) to maximize Blood-Brain Barrier (BBB) penetration of potential therapies for various CNS-related diseases.
In January 2022, ABL Bio signed an exclusive collaboration and exclusive worldwide license agreement for ABL301 with Sanofi. Both companies formed a Joint Research and Development Committee and have collaborated to develop ABL301. This manufacturing technology transfer of ABL301 is also conducted as part of the agreement. ABL301 is currently undergoing Phase 1 clinical trial in the Unted States under the leadership of ABL Bio, and Sanofi will conduct the trials from Phase 2 studies.
Sang Hoon Lee, CEO of ABL Bio said, “We have completed the manufacturing technology transfer for ABL301 and will receive additional milestone from Sanofi. The Phase 1 clinical trial for ABL301 in the U.S. is also undergoing smoothly,” and “Based on our collaboration with Sanofi, we will do our best to accelerate the clinical development of ABL301 and contribute to a better life for Parkinson’s disease patients.”
Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer and the top-line data will be disclosed in 2025. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).
Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.